01:23 , Apr 28, 2015 |  BC Extra  |  Company News

Management tracks

Diagnostics company Invitae Corp. (NYSE:NVTA) named Robert Nussbaum CMO, effective Aug. 1. Nussbaum was chief of the division of genomic medicine at the University of California San Francisco Medical Center; he will continue clinical activities...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Novartis, BioScrip Inc. hematology news

The U.S. District Court for the Southern District of New York unsealed a complaint filed by the U.S. government alleging that Novartis paid kickbacks to BioScrip to boost sales of iron chelating agent Exjade deferasirox...
08:00 , Jan 14, 2013 |  BioCentury  |  Strategy

Pricing Gattex

NPS Pharmaceuticals Inc. is the latest biotech to set a six-figure annual cost for an Orphan drug. While the company believes its Gattex teduglutide could reduce the overall cost of treating short bowel syndrome, the...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

NPS sales and marketing update

On Jan. 2, NPS said it set the annual list price for short bowel syndrome (SBS) drug Gattex teduglutide at $295,000. The company, which plans to launch the Orphan drug in February, said it has...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Clinical News

MuGard regulatory update

Access Pharmaceuticals said partner Rhei Pharmaceuticals Inc. (Hong Kong, China) received an acceptance letter from China's State Food and Drug Administration (SFDA) for MuGard mucoadhesive oral rinse to treat and prevent oral mucositis (OM). Rhei...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Company News

BioScrip management update

BioScrip Corp. (NASDAQ:BIOS), Elmsford, N.Y.   Business: Pharmaceuticals   Transitioning: Richard Smith to CEO from president and COO, effective Jan. 1, 2011; he will replace Richard Friedman, who will transition to non-executive chairman from chairman...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Access Pharmaceuticals, BioScrip sales and marketing update

Access launched its MuGard mucoadhesive oral rinse to treat and prevent oral mucositis (OM) in the U.S. The company said it received its first order of MuGard valued at more than $700,000 from its U.S....
01:49 , Aug 2, 2006 |  BC Extra  |  Company News

Robinson leaving Ligand

LGND said David Robinson resigned as chairman, president, CEO and a director to pursue other opportunities. Henry Blissenbach, who has been a LGND director since 1995, will become chairman and interim CEO. Blissenbach was previously...